HIGHLIGHTED ISSUES


Contents


Meaningful interpretation of subdiffusive measurements in living cells (crowded environment) by fluorescence fluctuation microscopy, Vol 11, Iss. 5, August 2010

Defining features and exploring chemical modifications to manipulate RNAa activity, Vol 11, Iss. 5, August 2010

Editorial [Hot topic: Current Strategies in Lead Discovery (Guest Editor: Maria L. Webb)] , Vol 11, Iss. 7, November 2010

Taking a systems approach to the identification of novel therapeutic targets and biomarkers, Vol 11, Iss. 7, November 2010

Open access high throughput drug discovery in the public domain: a Mount Everest in the making, Vol 11, Iss. 7, November 2010

Reprogramming of Normal and Cancer Stem Cells: Current Pharmaceutical Biotechnology, Vol 12, Iss. 2, February 2011

Infection, stem cells and cancer signals, Vol 12, Iss. 2, February 2011

Advances in whole genome sequencing technology, Vol 12, Iss. 2, February 2011

Molecular Imaging in Current Pharmaceuticals - Molecular Imaging Program at Stanford (MIPS) 1501, Palo Alto, CA 94304-5539, USA Current Pharmaceutical Biotechnology, Vol 12, Iss. 4, April 2011

ABC Transporters in Pharmacology/Physiology and Human Diseases -St. John's University, 8000 Utopia Parkwa Queens, NY 11439 USA Current Pharmaceutical Biotechnology, Vol 12, Iss. 4, April 2011

Stem cells therapies in basic science and translational medicine: current status and treatment monitoring strategies, Vol 12, Iss. 4, April 2011

Molecular targeting of breast cancer: imaging and therapy, Vol 12, Iss. 4, April 2011

Imaging cellular receptors in breast cancers: an overview, Vol 12, Iss. 4, April 2011

The challenge of exploiting ABCG2 in the clinic, Vol 12, Iss. 4, April 2011

Advances in the molecular detection of ABC transporters involved in multidrug resistance in cancer, Vol 12, Iss. 4, April 2011

Drugs and Pregnancy. Current Pharmaceutical Biotechnology, Vol 12, Iss 5, May 2011

Fluorescence molecule counting for single-molecule studies in crowded environment of living cells without and with broken ergodicity, Vol 12, Iss 5, May 2011

Frontiers of Metabolomics - Going from Bench to Bedside Karolinska Institutet (Nobel Institute), Department of Oncology-Pathology Karolinska Biomics Center, SE-171 76 Stockholm Sweden Current Pharmaceutical Biotechnology, Vol 12, Iss 7, July 2011

Altered metabolism and newborn screening using tandem mass spectrometry: lessons learned from the bench to bedside, Vol 12, Iss 7, July 2011

Metabolic profiling in disease diagnosis, toxicology and personalized healthcare, Vol 12, Iss 7, July 2011

Lipid mediator profiling in pulmonary disease, Vol 12, Iss 7, July 2011

Elucidation of cellular metabolism via metabolomics and stable-isotope assisted metabolomics , Vol 12, Iss 7, July 2011

Relevance of Pharmacokinetics to Antibiotic Dosing in Critically Ill Patients. Current Pharmaceutical Biotechnology, Vol 12, Iss 12, December 2011

The present milestone of 12 years of continuous publication for Current Pharmaceutical Biotechnology (CPB) by Zeno Foldes-Papp, Editor-in-Chief of CPB. Current Pharmaceutical Biotechnology ,Vol 13, Iss 1, January 2012

Update on Inflammatory Processes Governing Atherosclerotic Plaque Vulnerability and Reperfusion Injury. Division of Cardiology Foundation for Medical Researches Faculty of Medicine University Hospital Geneva Switzerland. Current Pharmaceutical Biotechnology ,Vol 13, Iss 1, January 2012

New Methodology and Approaches to Intracellular Lipid Transport in Atherosclerosis and Cardiovascular Disease. Current Pharmaceutical Biotechnology ,Vol 13, Iss 2, February 2012